Biochemicals and Reagents

Bis(3,5-dibromosalicyl) succinate is a chemical compound that belongs to the group of ligands. It is an activator of ion channels and a ligand for receptor proteins. Bis(3,5-dibromosalicyl) succinate has been used as a high-purity reagent and research tool in cell biology and pharmacology studies. This compound can also be used to produce antibodies against peptides or other small molecules.

[Pyr1]apelin-13 (human) (CAS: 217082-60-5)

Btk inhibitor 2 is a protein kinase inhibitor that was developed to target the B-cell lymphoma tumor necrosis factor receptor. It binds to the ATP binding site of Btk and prevents activation of the kinase. This drug has been shown to be effective in treating cancer by inhibiting cancer-related genes and promoting apoptosis in cancer cells. The drug has also been shown to have an effect on skeletal muscle, with a dose-dependent response for increasing muscle mass and decreasing fat content.

4-(1H-Benzo[D]imidazol-1-yl)-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)benzamide (AQBT) is a potent and selective inhibitor of ion channels. AQBT has a high affinity for Na+ currents in the CNS and peripheral nervous system of rats. It is a potent blocker of α7 nicotinic acetylcholine receptors. This compound also inhibits the activity of the neuronal γ amino butyric acid type A receptor (GABAAR).

INCB9471 is a drug that inhibits the activity of human immunodeficiency virus (HIV) by binding to the viral reverse transcriptase enzyme. It has been shown to be active against HIV-1 and HIV-2, with low cytotoxicity for cells in vitro. INCB9471 can be used for the treatment of bone cancer or as a diagnostic agent for infectious diseases, such as tuberculosis or hepatitis B. The compound has not been tested in animals or humans for long-term toxicity, bowel disease, primary sclerosing cholangitis, or antiviral resistance. However, it has been shown to be efficacious in treating her2+ breast cancer and long-term efficacy (up to 3 years) in patients with chronic hepatitis C.

RPH-2823 is a cutting-edge biochemical reagent, meticulously synthesized through advanced organic chemistry processes. This compound is derived from a series of complex reactions involving proprietary modifications to enhance its stability and reactivity under physiological conditions. The intricate mode of action of RPH-2823 involves targeting specific biochemical pathways, allowing for precise interaction at the molecular level with target receptors or enzymes. It exhibits strong affinity and selectivity, making it a valuable tool in modulating biological activities. RPH-2823 finds extensive applications in biochemical research, particularly within cellular signaling and metabolic pathway studies. It serves as an indispensable resource for unraveling complex biological mechanisms, facilitating the identification and characterization of potential therapeutic targets. Scientists utilize RPH-2823 to gain insights into cellular processes, offering the potential for groundbreaking discoveries in pharmacology and biotechnology.

DOTA-tris(Acid)-Amido-dPEG®11-Maleimide is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. DOTA-tris(Acid)-Amido-dPEG®11-Maleimide is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

Draflazine is a fluorescent derivative of the fatty acid arachidonic acid that binds to the phospholipase A2 receptor. This binding inhibits the release of arachidonic acid from membrane phospholipids and blocks the synthesis of prostaglandins. Draflazine has been shown to increase cardiac function after myocardial infarction, which may be due to its inhibition of reactive oxygen species production and activation of adenosine receptors. The drug also has antinociceptive properties, which have been shown in animal models using nociceptive tests such as tail-flick, hot-plate, and writhing tests. These effects are mediated by G protein-coupled adenosine receptors (A1, A2A).

NVP-BBD130 is an orally administered, small molecule inhibitor of the mammalian target of rapamycin (mTOR) kinase. It was designed to selectively inhibit mTORC1. NVP-BBD130 has been shown to be a potent inhibitor of melanoma tumor growth in mice and also inhibits the activation of phosphoinositide 3-kinase and Akt. This compound has been evaluated in a pharmacokinetic study as well as a mouse model for melanoma with promising results. In addition, NVP-BBD130 was shown to have an acceptable safety profile in healthy volunteers.

IACS-8968 is a peptide that exhibits a high degree of specificity for the L-type voltage-gated calcium channels. It has been shown to inhibit these channels without affecting other ion channels, and it can also block the binding of an antibody to its antigen by competitive inhibition. IACS-8968 has a number of potential applications in life science research and cell biology. It may be used as a research tool to study protein interactions, receptor ligand binding, or pharmacology. The high purity of IACS-8968 makes it possible for researchers to work with milligram quantities.

m-dPEG®2-Tosylate is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. m-dPEG®2-Tosylate is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

TDN 345 is a catecholaminergic, blocker. It blocks the signal transduction pathway by inhibiting the neurotransmitter receptor and blocking the binding of neurotransmitters to their receptors. TDN 345 is administered orally, at doses ranging from 3 mg to 10 mg per day, to control levels of catecholamines in patients with carotid artery disease and cerebral vascular disease. TDN 345 has been shown to reduce the growth factor-mediated, cerebrovascular diseases. TDN 345 may also be useful in treating glioma and etidocaine-induced pain.

Amino-dPEG®24-Tris(-dPEG®24- Tris (m-dPEG®24)3)3 is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. Amino-dPEG®24-Tris(-dPEG®24- Tris (m-dPEG®24)3)3 is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

Custom research peptide; min purity 95%.

Custom research peptide; min purity 95%.

Custom research peptide; min purity 95%, TFA salt. For different specs please use the Peptide Quote Tool

Please enquire for more information about DYKDDDDK including the price, delivery time and more detailed product information at the technical inquiry form on this page

Custom research peptide; min purity 95%.

Custom research peptide; min purity 95%.

Custom research peptide; min purity 95%.

Custom research peptide; min purity 95%.